IQVIA™ Real-World Insights Bibliography

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
Affiliations(s): "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain"
Publication(s):  "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
Document Type(s): Article,
Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care,
  Add to report
 
 
Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
Affiliations(s): "1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 2 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 3 Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea 4 Kansai Electric Power Medical Research Institute, Kobe, Japan 5 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 6 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 7 Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 8 Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan 9 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan 10 Department of Cardiovascular Medicine, Saga University, Saga, Japan 11 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan 12 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan 13 Boehringer Ingelheim Korea Ltd, Seoul, Korea 14 IQVIA, Espoo, Finland 15 Boehringer Ingelheim International GmbH, Ingelheim, Germany 16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 17 Kansai Electric Power Hospital, Osaka, Japan "
Publication(s):  "JDI journal Virtual Conference: ACC, May 2021"
Document Type(s): Article,
Countries: Japan, Korea, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis,
  Add to report
 
 
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan
Author(s): Masanobu Ishii, Takashi Kawai, Kenichi Tsujita, Ataru Igarashi, Manabu Suzuki, Hisato Deguchi, Jovelle Fernandez
Affiliations(s): Masanobu Ishii Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University [Japan] Takashi Kawai Department of Gastroenterological Endoscopy, Tokyo Medical University [Japan] Kenichi Tsujita Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University [Japan] Ataru Igarashi Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo [Japan] Manabu Suzuki Japan Medical Office, Takeda Pharmaceutical Company Limited [Japan] Hisato Deguchi Japan Medical Office, Takeda Pharmaceutical Company Limited [Japan] Jovelle Fernandez Japan Medical Office, Takeda Pharmaceutical Company Limited [Japan]
Publication(s):  Circulation Journal
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2022
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal
Author(s): Nuno Marques 1, Laetitia Gerlier 2, Mafalda Ramos 3, Helder Pereira 4, Sérgia Rocha 5, Ana Catarina Fonseca 6, Ana André 7, Ricardo Melo 8, Eduard Sidelnikov 9
Affiliations(s): 1Department of Cardiology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. 2IQVIA, Zaventem, Belgium. 3IQVIA, Zaventem, Belgium. Electronic address: mafalda.ramos@iqvia.com. 4Department of Cardiology, Hospital Garcia de Orta, Almada, Portugal. 5Department of Cardiology, Hospital de Braga, Braga, Portugal. 6Department of Neurology, Hospital de Santa Maria, Universidade de Lisboa, Lisboa, Portugal. 7Department of Neurology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. 8Amgen SA, Portugal. 9Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Publication(s):  PMID: 33581948 DOI: 10.1016/j.repc.2020.05.019 IQVIA HEOR Zaventem Brussels
Revista Portuguesa de Cardiologia Volume 40, Issue 2, February 2021, Pages 109-115.
Document Type(s): Article,
Countries: Portugal,
Click here for the abstract
C:
Y:
Cardiovascular disease, Health economics,
2021
  L:
A:
English
Burden of illness, Clinical setting: Primary care, Prospective study,
  Add to report
 
 
Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE
Author(s): P. Escribano (1), S. Gaine (2), P. Biedermann (3), A. Muller (3), M. Valge (4), T. Lange (5), S. Söderberg (6)
Affiliations(s): 1 Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 de Octubre, Madrid, Spain 2 National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland 3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland 4 StatFinn Estonia OÜ, Tartu, Estonia (now IQVIA) 5 University Medical Center Regensburg, Regensburg, Germany 6 Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, Sweden
Publication(s):  JO - The Journal of Heart and Lung Transplantation VL - 40 IS - 4, Supplement SP - S109 PY - 2021 DA - 2021/04/01/ SN - 1053-2498
Document Type(s): Abstract,
Countries: Canada, Europe,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2021
  L:
A:
English
Epidemiological study, Observational study,
  Add to report
 
 
Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from the empagliflozin comparative effectiveness and safety (EMPRISE) study
Author(s): A. Karasik1 , S. Lanzinger2 , E. Chia-Hui Tan3 , D. Yabe4 , D. Jung Kim5 , W. H-H Sheu6 , C. MelzerCohen1 , R.W. Holl2 , K. Ha5 , T. Nyström7 , L. Niskanen8 , M. Linnemann Jensen9 , M.H. Kyaw10, J. Núñez11, EMPRISE EU and East Asia Study Group;
Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2 Inst. for Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine, Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 9 IQVIA, Copenhagen, Denmark, 10Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain
Publication(s):  https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
Document Type(s): Abstract,
Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Methodology, Population Based Study,
  Add to report
 
 
Cardiovascular Effectiveness of Empagliflozin Compared to DPP-4i in Routine Care in East Asia: Results from the EMPRISE study
Author(s): Dae Jung Kim, Wayne H.-H. Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Elise Chia-Hui Tan, Yusuke Taneda, Vanessa Lei, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Group, Boehringer Ingelheim International GmbH, Ingelheim, Germany, StatFinn - EPID Research an IQVIA Company, Espoo, Finland
Affiliations(s): 1 Ajou University, Suwon, South Korea; 2 Taichung Veterans General Hospital, Taichung, Taiwan; 3 Gachon University Gil Medical Center, Incheon, South Korea; 4 Kansai Electric Power Medical Research Institute, Kobe, Japan; 5 Gifu University Graduate School of Medicine, Gifu, Japan; 6 National Research Institute of Chinese Medicine, Taipei, Taiwan; 7 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 8 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 9 IQVIA, Espoo, Finland; 10 Boehringer Ingelheim International GmbH, Ingelheim, Germany; 11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12 Kansai Electric Power Hospital, Osaka, Japan
Publication(s):  J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 542. https://doi.org/10.1016/S0735-1097(21)01901-X
Document Type(s): Abstract, Presentation,
Countries: Japan, South Korea, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Methodology, Observational study,
  Add to report
 
 
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results
Author(s): T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen
Affiliations(s): Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland;
Publication(s):  European Journal of Heart Failure (2021)23(Suppl. S2) 2?322doi:10.1002/ejhf.2297
Document Type(s): Abstract, Article,
Countries: Finland, Germany, Israel, Spain, Sweden,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Meta analysis, Methodology, Population Based Study,
  Add to report
 
 
Use of Low Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitors (PCSK9i) Initiation
Author(s): Rymer JA, Mues KE, Monda KL, Bratton EW, Wirtz HS, Okerson T, Overman RA, Brookhart MA, Muntner P, Wang TY
Affiliations(s): From the Duke Clinical Research InstituteDurham NC (J.A.R., T.Y.W.); Center for Observational ResearchAmgen IncThousand Oaks CA (K.E.M., K.L.M., H.S.W., T.O.); IQVIA, Real?World Evidence SolutionsDurham NC (E.W.B.); NoviSci, IncDurham NC (R.A.O., M.A.B.); University of North Carolina at Chapel HillChapel Hill NC (M.A.B.); Department of EpidemiologyUniversity of Alabama at BirminghamAL (P.M.).
Publication(s):  Originally published24 Apr 2020https://doi.org/10.1161/JAHA.119.014347Journal of the American Heart Association. ;0:e014347
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Cardiovascular disease, Medication compliance,
2020
  L:
A:
English
Epidemiological study,
  Add to report
 
 
Concomitant use of drugs known to cause interactions with oral antiplatelets?polypharmacy in acute coronary syndrome outpatients in Finland
Author(s): Tuire Prami, Houssem Khanfir, Pål Hasvold, Eeva Reissell, Juhani Airaksinen, Ville Kytö
Affiliations(s): Ville Kytö: Heart Center, Turku University Hospital
Publication(s):  European Journal of Clinical Pharmacology (2020) 76:257?265
Document Type(s): Article,
Countries: Finland,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2020
  L:
A:
English
Population Based Study, Retrospective database analysis,
  Add to report
 
 
 1 of 52 Next Page Last Page